美国InVivoScribe 
美国Invivoscribe公司致力于通过为分子诊断、血液病学研究诊断和cDNA合成提供高品质、可信赖、尖端的产品来提高世界医疗保健的水平。
1995年，在拥有体内cDNA合成技术专利的基础上Invivoscribe公司成立了。这种体内cDNA合成技术能在活细胞和组织中使不稳定的分子信使RNA转化为稳定存在的cDNA，从而提高了cDNA产物的质量和多产性，避免了通过RNA提取在体内合成cDNA的困难和缺点。Invivoscribe提供了全面的依靠PCR技术的基因重组、染色体转位、基因突变的检测试剂和对照。客户遍布在世界各领先制药和生物技术行业、医学中心、癌症研究中心和分子检测中心等领域。Invivoscribe研究的体内诊断产品是用于白血病、淋巴瘤和淋巴组织增生性疾病的诊断和分类。具体检测指标有IgH基因重排、TCRB/TCRD/TCRG基因重排、BCL1/JH转位、BCR/ABL转位、FLT3突变以及PML/PARα转位等。
作为优选试验的组织，Invivoscribe公司为制药行业的发展提供检测和其他服务，同时也为特异性分析平台提供原始试剂。
Invivoscribe的基因重组产品和某些基因突变检测产品是唯一获得专利的产品。
最新产品：Invivoscribe厂家最新发展了符合欧洲标准的体外诊断产品。

invivoscribe的淋巴瘤、白血病的体外诊断试剂包括：
（1）试剂盒 包括B Cell Gene Rearrangement/Clonality Assays（B细胞基因重排分析）, T cell
Gene Rearrangement/Clonality Assays（T细胞基因重排分析）, Translocation Assays（转位分析）
和Mutation Assays（突变分析）。
（2）特异分析试剂 包括IGH (Immunoglobulin Heavy Chain), IGK (Immunoglobulin Kappa Light
Chain), IGL (Immunoglobulin Lambda Light Chain), TCRB (T Cell Receptor Beta Chain), TCRD(
T Cell Receptor Delta Chain), TCRG (T Cell Receptor Gamma Chain), BCL2/JH t(14;18),
BCR/ABL t(9;22), FLT3 Mutation.
（3）CE Marked Diagnostic Assays
- IdentiClone™ IGH Gene Rearrangement and Clonality Assays
- IdentiClone™ IGK Gene Rearrangement and Clonality Assays
- IdentiClone™ IGL Gene Rearrangement and Clonality Assays
- IdentiClone™ TCRB Gene Rearrangement and Clonality Assays
- IdentiClone™ TCRD Gene Rearrangement and Clonality Assays
- IdentiClone™ TCRG Gene Rearrangement and Clonality Assays
- IdentiClone™ BCL1/JH t(11;14) Translocation Assays
- IdentiClone™ BCL2/JH t(14;18) Translocation Assays

invivoscribe的淋巴瘤、白血病的体外诊断试剂的检测方法包括：
（1）Gel detection：样本、标准品都跑PAGE胶
（2）ABI Fluorescence Detection 要求用6FAM,HEX,或者NED荧光素标记
（3）Beckman Coulter CE/NAT Platforms 要求用D4,D3或者D2荧光素标记
（4）cy5.0 Fluorescence Detection
（5）Probe-Based for Quantitative Real-Time Detection
（6）SYRB-Green for Quantitative Real-Time Detection

InVivoScribe Technologies is a privately-held biotechnology company located in San Diego, California, with a sales and distribution office (InVivoScribe Technologies, SARL) located in La Ciotat, Provence, France.

The company is dedicated to improving the quality of healthcare worldwide by providing high quality, reliable, cutting-edge tools for molecular diagnostics, hematopathology and cDNA synthesis.

The company was founded in 1995 based upon InVivoScribe's patented in vivo cDNA synthesis technologies. These technologies convert unstable cellular messenger RNA into stable complementary DNA within the living cells and tissues - enhancing the quality and reproducibility of cDNA products and eliminating difficulties and bias associated with RNA extraction and in vitro methods for cDNA synthesis.

InVivoScribe provides a comprehensive selection of PCR-based gene rearrangement, chromosome translocation, and gene mutation testing reagents and controls. Customers include many of the world's leading pharmaceutical and biotechnology companies, medical centers, cancer research centers, reference laboratories and molecular testing centers.

Our research and in vitro diagnostic products are used to identify, classify and follow leukemias, lymphomas and other lymphoproliferative disease.

As a contract research organization, InVivoScribe provides tests and services to assist in the development of pharmaceutical agents and devices. We also produce OEM Reagents dedicated for use with specific analytical platforms.

InVivoScribe's gene rearrangement products, and certain of our gene mutation testing products are covered by exclusive-licensed patents. The company is debt-free and has been profitable since the beginning of this decade.